Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Catheter Precision (NYSE American: VTAK) engaged a strategic advisor on April 2, 2026 to formally market for sale its cardiac electrophysiology business. The process aims to monetize legacy medical device assets (LockeT and VIVO) that have FDA market clearance and the CE mark, while the company sharpens focus on its Flyte aviation platform. Management says the sale could unlock shareholder value and that monetization would position the company as a pure‑play aviation business through disciplined capital allocation and increased execution and transparency.
Catheter Precision (NYSE American: VTAK) reported full-year 2025 results and described a strategic expansion. Key 2025 metrics: revenue $819 thousand (+95% YoY), gross margin 92.3%, and net loss $17.2 million (including $7.8 million non-cash).
Post-year-end the company acquired Flyte, a revenue-generating regional air mobility operator, and completed financings to strengthen capital for a dual-platform strategy across medical devices and aviation.
Catheter Precision (NYSE American: VTAK) subsidiary Fly Flyte announced expansion of its Vision Jet-powered Hops short‑haul regional platform, operating three aircraft today with two additional Vision Jets under accepted bids and expected to be fully operational by Memorial Day 2026.
The Hops model targets flights under ~500 miles, offering private‑terminal access, rapid booking‑to‑boarding, AI-driven scheduling/pricing, right‑sized economics, and safety features (CAPS, Safe Return) to enable high‑frequency regional travel.
Catheter Precision (NYSE American: VTAK) launched Flyte Hops Florida on March 16, 2026, expanding its Flyte regional aviation network to cover the entire East Coast from Maine to Florida. A soft rollout in Florida produced more than $160,000 of inbound bookings on a single aircraft, supporting plans to operate at least five Cirrus Vision Jets by Memorial Day 2026.
Flyte targets short-haul routes using Cirrus Vision Jets equipped with CAPS parachute technology, focusing on underutilized regional airports and planned expansion into California and Texas later in 2026.
Catheter Precision (NYSE American: VTAK) announced institutional financing commitments of up to $88 million and the completed acquisition of Flyte, positioning the company to scale a national regional aviation platform.
Funds are intended to support fleet expansion, market growth, platform scaling, balance sheet simplification and reduction of legacy liabilities; the transaction is subject to customary closing conditions including shareholder approval.
VTAK (NYSE American: VTAK) completed acquisition of the remaining 80.02% equity interest in Fly Flyte, making Flyte a wholly owned subsidiary and consolidating a revenue-generating, asset-backed regional aviation platform.
Flyte operates under FAA 14 CFR Part 135 using certified Cirrus Vision Jets, providing immediate cash flow, tangible aircraft and infrastructure, and consolidated revenues going forward.
Catheter Precision (NYSE American: VTAK) said its LockeT suture retention device will be featured in live procedural cases at the International Symposium of Left Atrial Appendage (ISLAA) 2026, held March 5–6, 2026, in Los Angeles.
Company representatives will provide hands-on demonstrations for electrophysiology fellows and highlight LockeT benefits including potential cost reduction and same-day discharge.
Catheter Precision (NYSE American: VTAK) announced a definitive agreement to sell its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer on Feb 19, 2026.
Transaction delivers an upfront cash payment of $15,000, a 5% equity stake in the buyer with anti-dilution protection tied to up to $5 million additional equity, and a 10-year royalty on net sales starting at 1.5% and rising to 3% for quarters above $5 million. Company says proceeds will strengthen the balance sheet and sharpen focus on electrophysiology growth.
VTAK (NYSE American: VTAK) acquired a 19.98% strategic minority stake in Fly Flyte, Inc. on Feb. 17, 2026, gaining immediate exposure to a revenue-generating, FAA Part 135 certified regional operator using AI-enabled operations and a fleet of Cirrus Vision Jets.
The investment preserves Flyte control, targets scalable fleet expansion, and provides optionality for increased ownership or future monetization while aligning VTAK with short-haul regional mobility ahead of potential eVTOL commercialization.
Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth. The company converted approximately $9 million of short and long-term liabilities into equity and extended note maturities to two and three years, strengthening liquidity and aligning with long-term investors.
The company said no future equity lines or forward-priced agreements are anticipated; additional transaction details are available in its Form 8-K filings.